Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Compass Pathways plc

NASDAQ: CMPS · Life Sciences · 2 alerts · CIK 1816590

Share price
$8.27Close, Nov 16
Market cap
$1.17B
Shares outstanding
141.71MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Compass Pathways plc filings on SEC EDGAR ↗

8:22 AM ET 8-K
Financial Results

Compass Pathways Financial Results

Compass Pathways reported Q3 2026 financial results, highlighting a strong cash position of $444 million and the imminent completion of its rolling NDA submission for COMP360 in treatment-resistant depression (TRD). The company expects a potential commercial launch in the first half of 2027, supported by positive Phase 3 data and a National Priority Voucher that could accelerate FDA review.

Term
Q3 2026

“Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm.”

Kabir Nath, Chief Executive Officer of Compass Pathways
8:07 AM ET 10-Q
Financial Results

Compass Pathways Q3 2026 Results: Net Loss of $9.83M, Loss Narrows

COMPASS Pathways plc is advancing its COMP360 psilocybin treatment, currently in Phase 3 for treatment-resistant depression (TRD) and Phase 2b/3 for PTSD. The company reported 141,710,353 shares outstanding as of October 28, 2026, and maintains a loan agreement with Hercules Capital for up to $100 million to support its clinical and commercialization efforts.

Key figure
Net loss $9.83M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.